WO2019157823A1 - Procédé de préparation de l-alanyl-l-glutamine, enzyme pour la préparation de l-alanyl-l-glutamine, et application - Google Patents

Procédé de préparation de l-alanyl-l-glutamine, enzyme pour la préparation de l-alanyl-l-glutamine, et application Download PDF

Info

Publication number
WO2019157823A1
WO2019157823A1 PCT/CN2018/107535 CN2018107535W WO2019157823A1 WO 2019157823 A1 WO2019157823 A1 WO 2019157823A1 CN 2018107535 W CN2018107535 W CN 2018107535W WO 2019157823 A1 WO2019157823 A1 WO 2019157823A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
gene
seq
acid ester
dipeptide
Prior art date
Application number
PCT/CN2018/107535
Other languages
English (en)
Chinese (zh)
Inventor
傅荣昭
李振伟
张贵慰
Original Assignee
邦泰生物工程(深圳)有限公司
邦泰合盛生物科技（深圳）有限公司
江西安泽麦生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 邦泰生物工程(深圳)有限公司, 邦泰合盛生物科技（深圳）有限公司, 江西安泽麦生物科技有限公司 filed Critical 邦泰生物工程(深圳)有限公司
Priority to CN201880014704.0A priority Critical patent/CN110382705B/zh
Priority to PCT/CN2018/107535 priority patent/WO2019157823A1/fr
Publication of WO2019157823A1 publication Critical patent/WO2019157823A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Definitions

  • the invention relates to the technical field of biomedicine, in particular to a preparation method of propargedopeptide, an enzyme for preparing proglycol dipeptide and an application thereof.
  • Proglycol dipeptide also known as L-Alanyl-L-Glutamine (Ala-Gln) is a biologically active dipeptide composed of alanine and glutamine residues. A dipeptide molecule that is stable in nature and readily soluble in water. Studies have shown that proglycol dipeptide has a variety of pharmacological activities, such as can promote muscle protein synthesis, improve clinical and biochemical indicators of critically ill patients; maintain intestinal function, maintain the body's nitrogen balance; enhance the role of the immune system. At present, proglycol dipeptide has been widely used in the treatment of serious infections, trauma, major surgery, extensive burns and malignant tumors.
  • the existing process mainly synthesizes proglycol dipeptide by chemical synthesis.
  • these chemical synthesis methods usually have complicated synthesis processes, many intermediate links, easy formation of by-products, difficulty in purification of the target product, harsh synthesis conditions, and often use some toxic and harmful substances.
  • the present invention provides a method for preparing a tragadipeptide, an enzyme for preparing a propanol dipeptide, and an application thereof; and the preparation method of the invention adopts a biological enzymatic method, which has the advantages of simple process, low cost, high yield and environmental protection.
  • the present invention provides a method for preparing a proglycol dipeptide, comprising:
  • the reaction solution is prepared by using L-alanine methyl ester hydrochloride and L-glutamine as a substrate in the presence of ⁇ -amino acid ester acyltransferase (XPD), and the pH of the reaction solution is adjusted to 7.0-9.0.
  • XPD ⁇ -amino acid ester acyltransferase
  • the proglycol dipeptide is collected;
  • the ⁇ -amino acid ester acyltransferase is derived from Elizabethkingia meningoseptica;
  • the amino acid sequence of the ⁇ -amino acid ester acyltransferase includes The amino acid sequence shown in any one of SEQ ID NO: 1 to SEQ ID NO: 6.
  • the gene coding sequence of the ⁇ -amino acid ester acyltransferase includes the nucleotide sequence shown in any one of SEQ ID NO: 7 to SEQ ID NO: 12.
  • the ⁇ -amino acid ester acyltransferase has outstanding biological activity and strong specificity, and is capable of efficiently catalyzing the conversion of L-alanine methyl ester hydrochloride and L-glutamine to propionol dipeptide.
  • the gene encoding the amino acid sequence shown by SEQ ID NO: 1 includes the nucleotide sequence shown in SEQ ID NO: 7.
  • the gene encoding the amino acid sequence shown by SEQ ID NO: 2 includes the nucleotide sequence shown in SEQ ID NO: 8.
  • the coding gene of the amino acid sequence shown in SEQ ID NO: 3 - SEQ ID NO: 6 includes the nucleotide sequence shown in SEQ ID NO: 9 - SEQ ID NO: 12, respectively.
  • the gene encoding the ⁇ -amino acid ester acyltransferase should consider a degenerate base, ie, the coding gene of the amino acid sequence shown in SEQ ID NO: 1 includes the nucleoside as shown in SEQ ID NO: 2.
  • the acid sequence, the protection range should also protect the nucleotide sequence having the base degeneracy of SEQ ID NO: 2, and the amino acid sequence corresponding to these nucleotide sequences is still SEQ ID NO: 1.
  • the gene encoding the amino acid sequence shown in SEQ ID NO: 2 - SEQ ID NO: 6 should also consider degenerate bases.
  • the L-alanine methyl ester hydrochloride has the molecular formula C 4 H 9 NO 2 HCl, and the chemical structure is as shown in Formula I; the L-glutamine has a molecular formula of C 5 H 10 N 2 O 3 , the chemical structure is shown in Formula II; the proglycol dipeptide has a molecular formula of C 8 H 15 N 3 O 4 , and the chemical structure is as shown in Formula III.
  • the preparation method of the present invention adopts a biological enzymatic method, and the L-alanine methyl ester hydrochloride and the L-glutamine form a proglycol dipeptide under the catalysis of an ⁇ -amino acid ester acyltransferase.
  • the pH of the reaction solution is adjusted to be 7.0-9.0. Further optionally, the pH of the reaction solution is adjusted to be 8.0 to 9.0. For example, the pH of the reaction solution is adjusted to 8.2, or 8.5, or 9.0.
  • the reaction temperature of the reaction solution is constant at 20-40 °C. Further optionally, the reaction temperature of the reaction liquid is constant at 20 to 30 °C. For example, the reaction temperature of the reaction solution is constant at 20 ° C, or 23 ° C, or 25 ° C, or 30 ° C, or 35 ° C.
  • the reaction time of the reaction is from 20 to 120 min. Further optionally, the stirring time of the stirring reaction is 20-30 min.
  • the content of proglycol dipeptide can be monitored by using a detection means, and the reaction is stopped after the propionate dipeptide is no longer increased; the detection means includes a liquid chromatography detection method.
  • the method for preparing the L-alanine methyl ester hydrochloride comprises: adding the thionyl chloride to the reaction kettle containing methanol at a temperature of 0-10 ° C; and then in the reaction kettle Adding L-alanine to the stirring reaction, the temperature is slowly raised to 25-30 ° C during the stirring reaction, and after the reaction is 0.5-1.0 hours, the temperature is further increased to 45-50 ° C and stirred. 1.0-2.0 hours; after completion of the reaction, the L-alanine methyl ester hydrochloride was collected.
  • the stirring reaction is stirred at a rate of 200-300 rpm.
  • the collection process of collecting the L-alanine methyl ester hydrochloride after the end of the reaction comprises obtaining the L-alanine methyl ester hydrochloride by a method of crystallization under reduced pressure.
  • the ⁇ -amino acid ester acyltransferase is added to the reaction solution in the form of an expression host cell or an enzyme powder.
  • the expression host cell refers to a host cell which contains a nucleotide sequence in which an ⁇ -amino acid ester acyltransferase is expressed, and which stably expresses the ⁇ -amino acid ester acyltransferase.
  • the gene is knocked out of the protease gene and/or peptidase gene expressing the host cell; the peptidase gene includes one or more of an aminopeptidase gene and a carboxypeptidase gene.
  • the gene knocks out one of the peptidase A (pepA) gene, the peptidase B (pepB) gene, the peptidase D (pepD) gene, and the peptidase N (pepN) gene of the expression host cell.
  • pepA peptidase A
  • pepB peptidase B
  • pepD peptidase D
  • pepN peptidase N
  • the process of knocking out the protease gene and/or peptidase gene of the host cell comprises: designing a primer, genetically recombining the expression host cell by gene editing technology, and knocking out the protease gene And/or the peptidase gene.
  • the primer comprises the nucleotide sequence set forth in SEQ ID NO: 13 - SEQ ID NO: 36.
  • the gene knocking out the protease gene and/or peptidase gene expressing the host cell comprises: designing a primer, and performing genetic recombination on the expression host cell by using CRISPR/Cas9 gene editing technology, The protease gene and/or the peptidase gene is knocked out, and the primer includes the nucleotide sequence shown as SEQ ID NO: 13 - SEQ ID NO: 36.
  • the expression host cell comprises one or more of E. coli and yeast.
  • the Escherichia coli may be Escherichia coli JM109 (DE3) or Escherichia coli BL21 (DE3).
  • the present invention preferably has an E. coli expression system with a short culture period, low preparation cost, and high enzyme yield.
  • the expression host cell engineered by gene knockout has a more stable and more efficient expression of the ⁇ -amino acid ester acyltransferase; at the same time, the expression host cell can also release the ⁇ -amino acid having high biological activity in a larger amount. Ester acyltransferase.
  • the process of collecting the proglycol dipeptide comprises separating the reaction solution and then obtaining the proglycol dipeptide.
  • the ⁇ -amino acid ester acyltransferase is added to the reaction solution in the form of an expression host cell, most of the L-alanine methyl ester hydrochloride and the L-glutamine enter To the intracellular of the expression host cell, the proglycol dipeptide is obtained under the catalysis of the intracellular ⁇ -amino acid ester acyltransferase and released into the extracellular reaction solution, and a small portion of the L-alanine
  • the proteyl dipeptide is obtained by catalyzing the acid methyl ester hydrochloride and the L-glutamine in the reaction liquid in the reaction of the ⁇ -amino acid ester acyltransferase.
  • the reaction may be stopped by isolating the expression host cell; the isolated
  • proglycol dipeptide is a short peptide product, it is often accompanied by decomposition of proglycol dipeptide when catalyzed by a biological enzyme prepared by a conventional prior art; since the biological enzyme system contains a large amount of protease and/or The peptidase, which is decomposed by the proteoglycan and/or peptidase, will greatly affect the yield of proglycol dipeptide.
  • the ⁇ -amino acid ester acyltransferase prepared by knocking out the expression gene of the protease gene and/or peptidase gene of the present invention can efficiently catalyze the production of proglycol dipeptide; meanwhile, the expression host cell does not produce protease and/or peptidase Does not decompose intracellular or extracellular proglycol dipeptide.
  • the efficiency of the intracellular ⁇ -amino acid ester acyltransferase to catalyze the production of proglycol dipeptide is higher than the efficiency of the catalyzed production of proglycol dipeptide by the ⁇ -amino acid ester acyltransferase released by the host cell in the reaction solution.
  • the expression host cells have a mass fraction in the reaction solution of 1% to 5%. Further, optionally, the expression host cells have a mass fraction in the reaction solution of 1% to 3%.
  • the expression host cell can be, but is not limited to, added to the reaction solution as an expression host cell solution.
  • the expression host cell solution further comprises a buffer, and the buffer comprises any one or more of a phosphate buffer solution, a borate buffer solution, and a Tris-HCl buffer solution.
  • the buffer also includes other types of buffers.
  • the concentration of the buffer is 10-500 mmol/L.
  • the concentration of the buffer is from 200 to 500 mmol/L.
  • the concentration of the buffer is 100 mmol/L, or 200 mmol/L, or 500 mmol/L.
  • the mass fraction of the L-alanine methyl ester hydrochloride in the reaction solution is 3%-15%; the L-alanine methyl ester hydrochloride and the L-Valley
  • the mass ratio of aminoamide is 1: (0.3-2).
  • the mass fraction of the L-alanine methyl ester hydrochloride in the reaction liquid is 10% to 15%.
  • the mass fraction of the L-alanine methyl ester hydrochloride in the reaction liquid is 5%, or 10%, or 15%, or 20%.
  • the mass ratio of the L-alanine methyl ester hydrochloride to the L-glutamine is 1: (0.5-1.5).
  • the mass ratio of the L-alanine methyl ester hydrochloride to the L-glutamine is either 1:0.8, or 1:1, or 1:1.2.
  • the mass ratio of the L-glutamine to the ⁇ -amino acid ester acyltransferase is 1: (0.1-2). Further, optionally, the mass ratio of the L-glutamine to the ⁇ -amino acid ester acyltransferase is 1: (0.5-1).
  • the preparation method of the proglycol dipeptide provided by the first aspect of the invention adopts the biological enzymatic method, the whole process is simple and efficient, the green is safe, the cost is low, and the time is short; the proglycol dipeptide obtained by the preparation method has extremely high Yield.
  • the present invention provides an enzyme for preparing a propanol dipeptide, the preparation enzyme comprising an ⁇ -amino acid ester acyltransferase derived from Escherichia coli;
  • the amino acid sequence of the ⁇ -amino acid ester acyltransferase includes the amino acid sequence shown in any one of SEQ ID NO: 1 to SEQ ID NO: 6.
  • the gene coding sequence of the ⁇ -amino acid ester acyltransferase includes the nucleotide sequence shown in any one of SEQ ID NO: 7 to SEQ ID NO: 12.
  • the ⁇ -amino acid ester acyltransferase is expressed in an expression host cell by constructing a recombinant plasmid, and the vector plasmid of the recombinant plasmid is a pET28a(+) vector plasmid. Inserting the gene coding sequence of the ⁇ -amino acid ester acyltransferase into the pET28a(+) vector plasmid to obtain a recombinant plasmid, which can be efficiently and efficiently produced in heterologous expression in an expression host cell. Alpha-amino acid ester acyltransferase.
  • the gene coding sequence of the ⁇ -amino acid ester acyltransferase is inserted into the multiple cloning site region of the pET28a(+) vector plasmid.
  • the gene coding sequence for the alpha-amino acid ester acyltransferase can be, but is not limited to, inserted between the BamH I and Hind III restriction sites of the pET28a(+) vector plasmid.
  • the 5' end of the gene coding sequence of the ⁇ -amino acid ester acyltransferase may be added with a start codon (such as ATG).
  • a start codon such as ATG.
  • the 3' end can be ligated with a stop codon (such as TAA) and a Hind III restriction site in the pET28a(+) vector plasmid.
  • the nucleotide sequence of the His-tag (histidine tag) is added to the gene coding sequence of the ⁇ -amino acid ester acyltransferase, so that the expressed protein can be tagged with His tag, and the His tag is favorable for expression. Isolation and purification of proteins, and analysis and tracking in experiments, such as analysis used in immunoblot experiments.
  • the enzyme- ⁇ -amino acid ester acyltransferase prepared by the second aspect of the present invention has good biological activity and high purity; and the preferred ⁇ -amino acid ester acyltransferase of the present invention has more than the conventional method. High yield, short time, and more biological activity and specificity.
  • the alpha-amino acid ester acyltransferase is prepared by expressing a host cell; the expression host cell comprises one or more of E. coli and yeast.
  • the gene is knocked out of the protease gene and/or peptidase gene expressing the host cell; the peptidase gene includes one or more of an aminopeptidase gene and a carboxypeptidase gene.
  • the process of knocking out the protease gene and/or peptidase gene of the host cell comprises: designing a primer, and performing genetic recombination on the expression host cell by using CRISPR/Cas9 gene editing technology, and knocking out The protease gene and/or the peptidase gene, the primer comprising the nucleotide sequence set forth in SEQ ID NO: 13 - SEQ ID NO: 36.
  • the third aspect of the present invention provides a biocatalytic use of an ⁇ -amino acid ester acyltransferase derived from a meninges of a gene containing the ⁇ -amino acid ester acyltransferase derived from the meninges
  • An alpha-amino acid ester acyltransferase gene encoding an E. aureus strain, the gene coding sequence of the ⁇ -amino acid ester acyltransferase comprising the nucleoside as shown in any one of SEQ ID NO: 7 to SEQ ID NO: 12.
  • An acid sequence; the alpha-amino acid ester acylase catalyzes the conversion of L-alanine methyl ester hydrochloride and L-glutamine to form proglycol dipeptide.
  • the preparation method of the invention adopts the biological enzymatic method, has high conversion rate, low cost and green safety, and can be widely applied to industrial scale production;
  • the preparation enzyme- ⁇ -amino acid ester acyltransferase used in the preparation method of the present invention has outstanding biological activity and strong specificity, and can efficiently catalyze L-alanine methyl ester hydrochloride and L. - conversion of glutamine to proglycol dipeptide;
  • the final concentration of the substrate can reach 3%-15%, which is much higher than the final concentration of the traditional process substrate;
  • the expression host cell modified by gene knockout can more efficiently and efficiently express ⁇ -amino acid ester acyltransferase in the cell and release the reaction solution, which can greatly improve the reaction conversion rate, and the prepared proglycol dipeptide yield is higher and purity. better.
  • FIG. 1 is a plasmid map of a recombinant plasmid pET28a-XPD02 according to an embodiment of the present invention
  • FIG. 2 is a view showing a nuclear magnetic resonance spectrum of proglycol dipeptide according to an embodiment of the present invention
  • FIG. 3 is a diagram showing a propionol dipeptide nuclear magnetic carbon spectrum according to an embodiment of the present invention.
  • the ⁇ -amino acid ester acyltransferase XPD-01 is obtained by experimental screening, and the nucleotide sequence of the ⁇ -amino acid ester acyltransferase XPD01 is the nucleotide sequence shown in SEQ ID NO: 37;
  • the ⁇ -amino acid ester acyltransferase XPD-01 was genetically modified by reverse PCR to prepare ⁇ -amino acid ester acyltransferase XPD-02 to XPD- 07; wherein the nucleotide and amino acid sequences corresponding to the ⁇ -amino acid ester acyltransferases XPD-02 to XPD-07 are shown in Table 2:
  • the PCR amplification procedure was: predenaturation at 98 ° C for 2 min; denaturation at 98 ° C for 10 s; annealing at 55-65 ° C for 30 s; extension at 72 ° C for 7 min; after 30 cycles, extension at 72 ° C for 10 min.
  • the PCR product was purified by a gel recovery kit, and then digested with restriction endonucleases respectively, and digested and ligated to plasmid pET28a (+) with T4 ligase. The plasmid was extracted, and the recombinant plasmid obtained after successful sequencing was obtained.
  • ⁇ -amino acid ester acyltransferase XPD-02 as an example, an upstream primer and a downstream primer are provided, and a gene coding sequence of an ⁇ -amino acid ester acyltransferase (XPD-02) obtained by an experiment; the ⁇ -amino acid
  • the gene coding sequence of the ester acyltransferase XPD-02 comprises the nucleotide sequence shown as SEQ ID NO: 1;
  • the gene coding sequence of XPD-02 was inserted between the BamH I and Hind III restriction sites of the pET28a(+) vector plasmid.
  • the gene coding sequence of XPD-02 is inserted into the pET28a(+) vector plasmid, the 5' end of the XPD gene coding sequence is added with a start codon (such as ATG) and the pET28a (+) vector plasmid is digested with BamHI. The sites are ligated, and a stop codon (such as TAA) is added to the 3' end to be ligated to the Hind III restriction site in the pET28a(+) vector plasmid. Then, the E.
  • coli competent cell DH5 ⁇ was transformed into a positive clone PCR and sequenced to identify a recombinant plasmid pET28a-XPD-02, such as the plasmid map of the recombinant plasmid pET28a-XPD-02 shown in FIG.
  • the other ⁇ -amino acid ester acyltransferase XPD-01, and the recombinant plasmid of XPD-03 to XPD-07 can also be obtained by referring to the above method.
  • An expression host cell is selected, the expression host cell comprising one or more of E. coli and yeast.
  • the prepared recombinant plasmid was transferred to an expression host cell, Escherichia coli, to express the corresponding ⁇ -amino acid ester acyltransferase XPD-01 to XPD-07.
  • Standard curve drawing set the injection volume and injection degree to 2 ⁇ L, 4 ⁇ L, 5 ⁇ L, 6 ⁇ L, 8 ⁇ L, respectively, and draw a standard curve; calculate the enzyme activity of ⁇ -amino acid ester acyltransferase XPD-01 to XPD-07 Data, and calculate the growth rate of the enzyme activity of the ⁇ -amino acid ester acyltransferase XPD-02 to XPD-07 obtained by genetic modification compared to the ⁇ -amino acid ester acyltransferase XPD-01, as shown in Table 3 below:
  • the experimental test results show that the ⁇ -amino acid ester acyltransferases XPD-02 to XPD-07 described in the present application have outstanding enzyme activities, and have higher enzyme activities than the ⁇ -amino acid ester acyltransferase XPD-01.
  • the growth rate and pH stability also have a large range of growth, especially the growth rate of the enzyme activity of the ⁇ -amino acid ester acyltransferase XPD-04 is higher than 50%.
  • An expression host cell is selected, the expression host cell comprising one or more of Escherichia coli and yeast.
  • the Escherichia coli may be Escherichia coli JM109 (DE3) or Escherichia coli BL21 (DE3).
  • Recombination of the expression host cells using the CRISPR/Cas9 gene editing technique includes the following steps:
  • the primers were designed to use pSGF/PASGR, PBSGF/PBSGR, PDSGF/PDSGR and PNSGF/PNSGR primer pairs, and pTargetF was used as a template to PCR-approve pTargetF which recognizes pepA, pepB, pepD and pepN genes.
  • the sgRNA complementary to the 20 bp base of the target fragment in the genome is then designated as sgRNA-pepA, sgRNA-pepB, sgRNA-pepD and sgRNA-pepN, respectively; then the amplified PCR product is transformed into E.
  • coli DH5 ⁇ coli DH5 ⁇ , respectively, and utilized The above primers were used to identify positive clones and sequenced, and the positive clones with the correct sequencing were named pTargetF-pepA, pTargetF-pepB, pTargetF-pepD and pTargetF-pepN, respectively.
  • pepA, pepB, pepD and pepN genes for homologous recombination with primers PA01/PA02 and PA03/PA04, PB01/PB02 and PB03/PB04, PD01/PD02 and PD03/PD04, PN01/PN02 and PN03/PN04, respectively
  • Upstream and downstream homology arm fragments pepA up/down, pepB up/down, pepD up/down and pepN up/down, then pepA up/down, pepB up/down, pepD up/down by overlap PCR (Overlap PCR) Connected to the top/bottom of pepN respectively, the correct sequencing of the sequencing strips is named pepA, pepB, pepD and pepN.
  • the PA01 comprises the nucleotide sequence set forth in SEQ ID NO: 13; the PA02 comprises the nucleotide sequence set forth in SEQ ID NO: 14; and the PA03 comprises as set forth in SEQ ID NO: 15. a nucleotide sequence; the PA04 comprises a nucleotide sequence as set forth in SEQ ID NO: 16; the PASGF comprises a nucleotide sequence as set forth in SEQ ID NO: 17; and the PASGR comprises as SEQ ID NO : nucleotide sequence shown in 18.
  • the PB01 comprises a nucleotide sequence as set forth in SEQ ID NO: 19; the PB02 comprises a nucleotide sequence as set forth in SEQ ID NO: 20; the PB03 comprises a nucleus as set forth in SEQ ID NO: a nucleotide sequence; the PB04 comprising the nucleotide sequence set forth in SEQ ID NO: 22; the PBSGF comprising the nucleotide sequence set forth in SEQ ID NO: 23; the PBSGR comprising SEQ ID NO: 24 The nucleotide sequence shown.
  • the PD01 comprises a nucleotide sequence as set forth in SEQ ID NO: 25; the PD02 comprises a nucleotide sequence as set forth in SEQ ID NO: 26; and the PD03 comprises a nucleus as set forth in SEQ ID NO: a nucleotide sequence; the PD04 comprises a nucleotide sequence as set forth in SEQ ID NO: 28; the PDSGF comprises a nucleotide sequence as set forth in SEQ ID NO: 29; and the PDSGR comprises SEQ ID NO: 30 The nucleotide sequence shown.
  • the PN01 comprises a nucleotide sequence as set forth in SEQ ID NO: 31; the PN02 comprises a nucleotide sequence as set forth in SEQ ID NO: 32; and the PN03 comprises a nucleus as set forth in SEQ ID NO: a nucleotide sequence; the PN04 comprises a nucleotide sequence as set forth in SEQ ID NO: 34; the PNSGF comprises a nucleotide sequence as set forth in SEQ ID NO: 35; and the PNSGR comprises as SEQ ID NO: 36 The nucleotide sequence shown.
  • the pCas was transformed into the expression host cell, then the monoclonal containing pCas was picked, and then added to the LB medium of 50 mg/L kanamycin, and cultured at 30 ° C, 200 rpm until the OD 600 was 0.2, and added to the shake flask.
  • Arabinosine at a final concentration of 10 mM induced expression of the ⁇ -Red protein on the pCas vector then was shaken to an OD 600 of 0.6 to recover the expression host cells and prepare for electroporation.
  • pTargetF plasmid including one or more of pTargetF-pepA, pTargetF-pepB, pTargetF-pepD and pTargetF-pepN
  • 400 ng of homologous arm DNA were added to 100 ⁇ L of the prepared competent cells.
  • Fragments including one or more of pepA, pepB, pepD and pepN
  • a pre-cooled 0.2cm electric rotor placed in an electrorotator at 2.2kv (Bio- Rad)
  • electro-transfer quickly add 1mL of LB medium, resuscitate at 30°C, 180rpm for 1h, apply LB double-antiplate containing 50mg/L kanamycin and 50mg/L spectinomycin, culture at 30°C.
  • the step of eliminating pTargetF and pCas comprises: culturing the recombinant expression host cell (containing pTargetF and pCas) in 50 mg/L kanamycin LB medium, and adding the final concentration to 0.5 mM IPTG to induce culture overnight, and It was applied to a plate containing 50 mg/L kanamycin for elimination of pTargetF, and a monoclonal was grown on the plate, and the monoclonal was picked up and cultured in liquid LB containing 50 mg/L spectinomycin overnight, not long. That is, the recombinant expression host cell depleted of pTargetF, and then the recombinant expression host cell was picked and cultured overnight at 42 ° C to eliminate pCas.
  • the constructed recombinant plasmid pET28a-XPD-02 was transferred into the recombinant expression host cell, and inoculated into 4 mL of LB medium at a dose of 1%.
  • XPD-02 was collected by sonication and centrifugation; and identified by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
  • SDS-PAGE SDS-polyacrylamide gel electrophoresis
  • the molecular sizes of XPD and XPD obtained by the expression in this embodiment are similar to the theoretical calculation values of the corresponding proteins, wherein the theoretical molecular weight of XPD-02 is 66.8 kDa.
  • the collected XPD-02 was further purified to obtain XPD-02 enzyme powder.
  • Other ⁇ -amino acid ester acyltransferases XPD-03 to XPD-07 can be prepared by the above preparation methods, and the present embodiment will not be discussed too much.
  • a method for preparing a propanol dipeptide comprising:
  • reaction substrate L-alanine methyl ester hydrochloride 20 g and glutamine 21 g were dissolved in pure water (400 mL), and 100 mL XPD-02 cell solution was slowly added to the reaction substrate, wherein XPD-02 cells were throughout.
  • the mass percentage in the reaction solution was 1.5%, and the pH of the reaction solution was monitored in real time, and the pH was adjusted to 8 with a 5 M sodium hydroxide solution, and the temperature was maintained at 25 °C.
  • the amount of proglycol dipeptide was determined by liquid chromatography after sampling and dilution. The reaction is stopped when the proglycol dipeptide begins to decompose.
  • the reaction solution was centrifuged, the supernatant was added to a final concentration of 20% methanol in a water bath at 60 ° C for 30 min, 0.5% activated carbon was stirred for 30 min, and centrifuged to obtain 625 mL of the supernatant reaction solution to obtain a propionol dipeptide content of 59.9 g/L, and a conversion rate of 92.0%.
  • the prepared propionol dipeptide was sampled and tested to obtain a propionol dipeptide nuclear magnetic resonance spectrum (Fig. 2) and a propionol dipeptide nuclear magnetic carbon spectrum (Fig. 3).
  • a method for preparing a propanol dipeptide comprising:
  • reaction substrate L-alanine methyl ester hydrochloride 20 g and glutamine 21 g were dissolved in pure water (400 mL), and 100 mL XPD-02 cell solution was slowly added to the reaction substrate, wherein XPD-02 cells were throughout.
  • the mass percentage in the reaction solution was 5.0%, and the pH of the reaction solution was monitored in real time, and the pH was adjusted to 9 with a 5 M sodium hydroxide solution, and the temperature was maintained at 40 °C.
  • the amount of proglycol dipeptide was determined by liquid chromatography after sampling and dilution. The reaction is stopped when the proglycol dipeptide begins to decompose.
  • the reaction solution was centrifuged, the supernatant was added to a final concentration of 20% methanol at 60 ° C for 30 min, 0.5% activated carbon was stirred for 30 min, and centrifuged to obtain 625 mL of the supernatant, and the content of proglycol dipeptide was 60.6 g/L, and the conversion rate was 93.0%.
  • a method for preparing a propanol dipeptide comprising:
  • reaction substrate L-alanine methyl ester hydrochloride 20 g and glutamine 21 g were dissolved in pure water (400 mL), and 100 mL of XPD-03 cell solution was slowly added to the reaction substrate, wherein XPD-03 cells were throughout.
  • the mass percentage in the reaction solution was 1.5%, and the pH of the reaction solution was monitored in real time, and the pH was adjusted to 8 with a 5 M sodium hydroxide solution, and the temperature was maintained at 25 °C.
  • the amount of proglycol dipeptide was determined by liquid chromatography after sampling and dilution. The reaction is stopped when the proglycol dipeptide begins to decompose.
  • the reaction solution was centrifuged, the supernatant was added to a final concentration of 20% methanol at 60 ° C for 30 min, 0.5% activated carbon was stirred for 30 min, and the supernatant was centrifuged to obtain 625 mL of the supernatant, the content of proglycol dipeptide was 60.4 g/L, and the conversion rate was 92.8%.
  • a method for preparing a propanol dipeptide comprising:
  • reaction substrate L-alanine methyl ester hydrochloride 20 g and glutamine 21 g were dissolved in pure water (400 mL), and 80 mL of XPD-04 cell solution was slowly added to the reaction substrate, wherein XPD-04 cells were throughout.
  • the mass percentage in the reaction solution was 1.5%, and the pH of the reaction solution was monitored in real time, and the pH was adjusted to 8 with a 5 M sodium hydroxide solution, and the temperature was maintained at 25 °C.
  • the amount of proglycol dipeptide was determined by liquid chromatography after sampling and dilution. The reaction is stopped when the proglycol dipeptide begins to decompose.
  • the supernatant was added to a final concentration of 20% methanol in a water bath at 60 ° C for 30 min, 0.5% activated carbon was stirred for 30 min, and the supernatant was centrifuged to obtain 600 mL of the supernatant, the content of proglycol dipeptide was 61.5 g/L, and the conversion rate was 94.5%.
  • a method for preparing a propanol dipeptide comprising:
  • reaction substrate L-alanine methyl ester hydrochloride 20 g and glutamine 21 g were dissolved in pure water (400 mL), and 100 mL of XPD-05 cell solution was slowly added to the reaction substrate, wherein XPD-05 cells were throughout the reaction.
  • the mass percentage in the liquid was 1.5%
  • the pH of the reaction solution was monitored in real time, the pH was adjusted to 8, and the temperature was maintained at 25 °C.
  • the amount of proglycol dipeptide was determined by liquid chromatography after sampling and dilution. The reaction is stopped when the proglycol dipeptide begins to decompose.
  • the reaction solution was centrifuged, the supernatant was added to a final concentration of 20% methanol in a water bath at 60 ° C for 30 min, 0.5% activated carbon was stirred for 30 min, and centrifuged to obtain 625 mL of the supernatant reaction solution, the content of proglycol dipeptide was 55.8 g/L, and the conversion rate was 85.7%.
  • a method for preparing a propanol dipeptide comprising:
  • reaction substrate L-alanine methyl ester hydrochloride 20 g and glutamine 21 g were dissolved in pure water (400 mL), and 90 mL of XPD-06 cell solution was slowly added to the reaction substrate, wherein XPD-05 cells were throughout.
  • the mass percentage in the reaction solution was 1.5%, and the pH of the reaction solution was monitored in real time, and the pH was adjusted to 8 with a 5 M sodium hydroxide solution, and the temperature was maintained at 25 °C.
  • the amount of proglycol dipeptide was determined by liquid chromatography after sampling and dilution. The reaction is stopped when the proglycol dipeptide begins to decompose.
  • the reaction solution was centrifuged, the supernatant was added to a final concentration of 20% methanol at 60 ° C for 30 min, 0.5% activated carbon was stirred for 30 min, and the supernatant was subjected to centrifugation to obtain 612.5 mL of the supernatant, and the content of proglycol dipeptide was 60.7 g/L, and the conversion rate was 93.2%.
  • a method for preparing a propanol dipeptide comprising:
  • reaction substrate L-alanine methyl ester hydrochloride 20 g and glutamine 21 g were dissolved in pure water (400 mL), and 50 mL of XPD-07 cell solution was slowly added to the reaction substrate, wherein XPD-07 cells were throughout.
  • the mass percentage in the reaction solution was 1.5%, and the pH of the reaction solution was monitored in real time, and the pH was adjusted to 8 with a 5 M sodium hydroxide solution, and the temperature was maintained at 25 °C.
  • the amount of proglycol dipeptide was determined by liquid chromatography after sampling and dilution. The reaction is stopped when the proglycol dipeptide begins to decompose.
  • the reaction solution was centrifuged, the supernatant was added to a final concentration of 20% methanol at 60 ° C for 30 min, 0.5% activated carbon was stirred for 30 min, and the supernatant was centrifuged to obtain 562.5 mL of the supernatant, the content of proglycidide was 60.9 g/L, and the conversion rate was 93.5%.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation de L-alanyl-L-glutamine, ledit procédé consistant : à utiliser, en présence d'une α-amino-acide ester acyltransférase, de l'hydrochlorure d'ester méthylique de L-alanine et de la L-glutamine en tant que substrats pour préparer une solution de réaction, à ajuster le pH de la solution de réaction à 7,0-9,0, et après la réaction à une température constante de 20 à 40°C, à recueillir la L-alanyl-L-glutamine. L'α-amino-acide ester acyltransférase est dérivée de Elizabethkingia meningoseptica, et la séquence d'acides aminés de l'α-amino-acide ester acyltransférase comprend la séquence d'acides aminés dans l'une quelconque de SEQ ID NO : 1 – SEQ ID NO : 6. Le procédé de préparation est très efficace, simple, à faible coût et respectueux de l'environnement, présente un taux de conversion élevé, et peut être largement appliqué dans la production industrielle. L'invention concerne également une enzyme pour la préparation de L-alanyl-L-glutamine, et une application.
PCT/CN2018/107535 2018-09-26 2018-09-26 Procédé de préparation de l-alanyl-l-glutamine, enzyme pour la préparation de l-alanyl-l-glutamine, et application WO2019157823A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880014704.0A CN110382705B (zh) 2018-09-26 2018-09-26 丙谷二肽的制备方法、丙谷二肽制备用酶及应用
PCT/CN2018/107535 WO2019157823A1 (fr) 2018-09-26 2018-09-26 Procédé de préparation de l-alanyl-l-glutamine, enzyme pour la préparation de l-alanyl-l-glutamine, et application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/107535 WO2019157823A1 (fr) 2018-09-26 2018-09-26 Procédé de préparation de l-alanyl-l-glutamine, enzyme pour la préparation de l-alanyl-l-glutamine, et application

Publications (1)

Publication Number Publication Date
WO2019157823A1 true WO2019157823A1 (fr) 2019-08-22

Family

ID=67619125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/107535 WO2019157823A1 (fr) 2018-09-26 2018-09-26 Procédé de préparation de l-alanyl-l-glutamine, enzyme pour la préparation de l-alanyl-l-glutamine, et application

Country Status (2)

Country Link
CN (1) CN110382705B (fr)
WO (1) WO2019157823A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113817790A (zh) * 2021-10-18 2021-12-21 精晶药业股份有限公司 一种固定化酶制备丙氨酰谷氨酰胺的方法
CN115160164A (zh) * 2022-05-06 2022-10-11 大连医诺生物股份有限公司 一种复合丙氨酸甲酯盐酸盐的制备方法及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112831451B (zh) * 2019-11-25 2022-09-16 中国科学院微生物研究所 产丙谷二肽的工程菌及其构建方法与应用
CN116286567B (zh) * 2022-09-27 2023-09-29 合肥工业大学 一株产α-氨基酸酯酰基转移酶的重组大肠埃希氏菌及其构建方法和应用
CN116640819B (zh) * 2023-07-20 2023-10-13 凯莱英生命科学技术(天津)有限公司 α-氨基酸脂酰基转移酶的制备方法及其在二肽合成上的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104480075A (zh) * 2014-11-20 2015-04-01 江苏诚信药业有限公司 一种催化合成丙谷二肽的生物酶及其制备方法和应用
CN105274174A (zh) * 2015-11-30 2016-01-27 精晶药业股份有限公司 一种生物酶转化制备丙谷二肽的方法
CN106834394A (zh) * 2017-01-20 2017-06-13 天津科技大学 一种丙谷二肽的制备方法
WO2018121458A1 (fr) * 2016-12-30 2018-07-05 大连医诺生物股份有限公司 Gène codant pour une enzyme biosynthétique de dipeptide alanyl-glutamine et son application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104480075A (zh) * 2014-11-20 2015-04-01 江苏诚信药业有限公司 一种催化合成丙谷二肽的生物酶及其制备方法和应用
CN105274174A (zh) * 2015-11-30 2016-01-27 精晶药业股份有限公司 一种生物酶转化制备丙谷二肽的方法
WO2018121458A1 (fr) * 2016-12-30 2018-07-05 大连医诺生物股份有限公司 Gène codant pour une enzyme biosynthétique de dipeptide alanyl-glutamine et son application
CN106834394A (zh) * 2017-01-20 2017-06-13 天津科技大学 一种丙谷二肽的制备方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113817790A (zh) * 2021-10-18 2021-12-21 精晶药业股份有限公司 一种固定化酶制备丙氨酰谷氨酰胺的方法
CN113817790B (zh) * 2021-10-18 2023-11-03 精晶药业股份有限公司 一种固定化酶制备丙氨酰谷氨酰胺的方法
CN115160164A (zh) * 2022-05-06 2022-10-11 大连医诺生物股份有限公司 一种复合丙氨酸甲酯盐酸盐的制备方法及应用

Also Published As

Publication number Publication date
CN110382705A (zh) 2019-10-25
CN110382705B (zh) 2022-07-15

Similar Documents

Publication Publication Date Title
WO2019157823A1 (fr) Procédé de préparation de l-alanyl-l-glutamine, enzyme pour la préparation de l-alanyl-l-glutamine, et application
CN109609475B (zh) 草铵膦脱氢酶突变体及其合成l-草铵膦的应用
CN110592036A (zh) 一种草铵膦脱氢酶突变体及在氧化-还原多酶偶联生产l-草铵膦中的应用
CN110157654B (zh) 一种纳豆芽孢杆菌重组菌及其构建方法与应用
CN110950937B (zh) 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
CN110885803A (zh) 重组草铵膦脱氢酶、基因工程菌及其在制备l-草铵膦中的应用
WO2023045682A1 (fr) Procédé d'augmentation de la quantité d'expression soluble d'un polypeptide
KR20190086016A (ko) L-알라닐-l-글루타민 생합성 효소를 코딩하는 유전자 및 그 용도
CN111117942A (zh) 一种产林可霉素的基因工程菌及其构建方法和应用
CN112358530B (zh) 多肽标签、高度可溶性的重组腈水解酶及其在医药化学品合成中的应用
WO2021120566A1 (fr) Bactéries génétiquement modifiées et leur application, et procédé de production de prostaglandine e2
CN115948402A (zh) 产5-氨基乙酰丙酸的重组希瓦氏菌及其应用
RU2697375C2 (ru) ПЛАЗМИДНЫЙ ВЕКТОР pRh15A ДЛЯ ПОЛУЧЕНИЯ БЕЗМЕТИОНИНОВОГО ИНТЕРФЕРОНА АЛЬФА-2b, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI BL21 DE3 - ПРОДУЦЕНТ БЕЗМЕТИОНИНОВОГО ИНТЕРФЕРОНА АЛЬФА-2b И СПОСОБ ПОЛУЧЕНИЯ БЕЗМЕТИОНИНОВОГО ИНТЕРФЕРОНА АЛЬФА-2b
CN108795832B (zh) 一种内源l-门冬酰胺酶ii基因敲除的宿主菌、其制备方法及其应用
CN110982796A (zh) 一种ama合成酶及其在合成ama或其衍生物中的应用
CN110628800A (zh) 一种手性醇高效生产重组菌的构建方法及其应用
CN116640743B (zh) 一种核酸内切酶及其应用
CN112831451B (zh) 产丙谷二肽的工程菌及其构建方法与应用
CN117486984B (zh) 转运蛋白KefG在提高L-肌肽产量中的应用
CN117925744B (zh) 非核糖体肽合成酶在生产脱羧肌肽中的应用
CN114672524B (zh) 一种催化非天然氨基酸衍生物的双功能血红素蛋白
CN114134126B (zh) 转氨酶及其突变体在制备(s)-1-甲氧基-2-丙胺中的应用
WO2012128661A1 (fr) Protéine hybride, souche de bactéries escheria productrice de protéine hybride et procédé de production d'interféron humain alpha-2b exempt de méthionine à partir de cette protéine hybride
US20230132468A1 (en) Method for preparing immobilized arginine deiminase (adi) and producing [14/15n]-l-citrulline
CN117821416A (zh) 一种胞苷激酶突变体及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18906255

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18906255

Country of ref document: EP

Kind code of ref document: A1